Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Moderna has developed a broad intellectual property estate including more than 250 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures.

Market valuation(2016-09-07)

$3 B

Patent Applications (May, 2017)

250

Company Growth (employees)

Type

Private

Cambridge, US

Size (employees)

480 (est)+4%

Website

modernatx.com

Moderna Therapeutics is headquartered in Cambridge, US

Key People at Moderna Therapeutics

Stephane Bancel

CEO

Lorence Kim

CFO

Stephen Hoge

President

Noubar Afeyan

Chairman & Co-Founder

Steve Harbin

SVP of Human Resources & Clinical Supply Operations

Marcello Damiani

Chief Digital Officer

Moderna Therapeutics Office Locations

Moderna Therapeutics has offices in Cambridge, Huddinge, Norwood and Canton

Cambridge, US (HQ)

320 Bent St

Huddinge, SE

Hälsovägen 7-9

Cambridge, US

200 Technology Square

Moderna Therapeutics Data and Metrics

Summary Metrics

Total Funding	$1.1 b
Latest funding size	$8 m
Time since last funding	12 months
Investors	RA Capital Management, Viking Global Investors, Invus, Alexion Pharmaceuticals, Bill & Melinda Gates Foundation, AstraZeneca, Flagship Ventures, Wellington Management

Moderna Therapeutics's latest funding round in September 2016 was reported to be $8 m. In total, Moderna Therapeutics has raised $1.1 b. Moderna Therapeutics's latest valuation is reported to be $3 b.